Press Release
SAN DIEGO, CA, Feb 22, 2012 (MARKETWIRE via COMTEX) --NuVasive, Inc. (NASDAQ: NUVA)
-- Fourth quarter 2011 total revenue of $150.2 million; up 16.2% from
fourth quarter 2010 and up 13.0% from third quarter 2011
-- Full year 2011 total revenue of $540.5 million; up 13.0% from the full
year 2010
-- GAAP net loss of $10.0 million, or $0.24 per share, for the fourth
quarter 2011 and $69.8 million, or $1.73 per share, for the full year
2011
-- Non-GAAP earnings of $11.4 million, or $0.27 per share, for the fourth
quarter 2011 and $43.9 million, or $1.07 per share, for the full year
2011
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today financial results for the quarter and for the full year ended December 31, 2011.
Alex Lukianov, Chairman and Chief Executive Officer, said, "Our financial performance in 2011 attests to the exceptional execution of our market-share taking strategy, which drove revenue growth of 13% within a challenged US spine market that did not grow. I am very proud of the NuVasive family's accomplishments to establish us as one of the top global spine companies with innovative surgical solutions that address the entire spine."
Mr. Lukianov continued, "As the spine market shifts toward more minimally invasive procedures, NuVasive is ready to further penetrate the market and we expect to again lead the industry in market share gains in 2012. Normalized for the full year impacts of certain 2011 events, we expect to improve the operating profile of our business in 2012, with a pre-tax earnings growth rate nearly two times the rate of revenue growth. Through the breadth of our procedural offerings, increased global expansion, and continued focus on superior clinical outcomes, we are well positioned to achieve our longer term goal of becoming the #3 company in spine with $1 billion in revenue and a greatly improved profitability profile."
NuVasive reported fourth quarter 2011 revenue of $150.2 million, a 16.2% increase over the $129.3 million for the fourth quarter 2010 and a 13.0% increase over the $132.9 million reported for the third quarter 2011.
Gross profit for the fourth quarter 2011 was $113.1 million and gross margin was 75.3%, compared to a gross profit of $106.2 million and a gross margin of 82.1% for the fourth quarter 2010. For the third quarter 2011, gross profit was $106.9 million and gross margin was 80.4%. Gross profit for the full year 2011 was $428.4 million and gross margin was 79.3%, compared to a gross profit of $393.1 million and gross margin of 82.2% for the full year 2010.
Total operating expenses for the fourth quarter 2011 were $122.9 million compared to $94.9 million in the fourth quarter 2010 and $198.3 million in the third quarter 2011. The higher operating expenses in the fourth quarter 2011 compared to the prior year resulted primarily from an intangible asset impairment charge and additional costs associated with higher revenue and infrastructure expansion. Full year 2011 operating expenses were $513.4 million compared to $361.0 million reported for the full year 2010. The higher operating expenses in 2011 resulted primarily from a charge related to intellectual property litigation, an intangible asset impairment charge, and additional costs associated with higher revenue and infrastructure expansion.
On a GAAP basis, the Company reported a net loss of $10.0 million, or $0.24 per share, for the fourth quarter 2011, and a net loss of $69.8 million, or $1.73 per share for the full year 2011.
On a Non-GAAP basis, the Company reported net income of $11.4 million, or $0.27 per share, for the fourth quarter 2011, and net income of $43.9 million, or $1.07 per share, for the full year 2011. The Non-GAAP earnings per share calculations for the fourth quarter and full year exclude, respectively, (i) non-cash stock-based compensation of $8.3 million and $32.1 million; (ii) certain intellectual property litigation expenses of $1.3 million and $7.0 million; (iii) litigation award expense of nil and $101.2 million; (iv) amortization of intangible assets of $2.4 million and $6.6 million; (v) acquisition related items of $1.4 million and $3.8 million; (vi) non-cash interest expense on convertible notes of $3.0 million and $6.1 million; (vii) the positive impact from certain transactions associated with convertible notes activity of $0.4 million and $2.1 million; (viii) certain discrete tax items of $0.3 million and $6.6 million; and (ix) an intangible asset impairment charge of $18.2 million and $18.2 million.
Cash, cash equivalents and short and long-term marketable securities were $342.2 million at December 31, 2011.
2012 Full Year Financial Guidance
Compared to 2011 financial results, 2012 guidance reflects the full year impacts of convertible note activity, the Impulse Monitoring business, an accrual for estimated patent litigation royalties, and a tax expense rate in comparison to a tax benefit rate.
-- Revenue of approximately $615 million -- GAAP EPS of approximately $0.09 -- Non-GAAP EPS of approximately $0.93 -- Non-GAAP Operating Margin of approximately 14% -- GAAP effective tax expense rate of approximately 60% -- Non-GAAP effective tax expense rate of approximately 40%
Reconciliation of Full Year EPS Guidance
2012
Guidance (1)
-------------
GAAP earnings per share guidance $ 0.09
Non-cash stock-based compensation 0.46
Certain intellectual property litigation
expenses 0.03
Amortization of intangible assets 0.16
Acquisition related items (2) 0.02
Non-cash interest expense on convertible
notes 0.17
-------------
Non-GAAP earnings per share guidance $ 0.93
=============
Weighted shares outstanding - basic (3) 43,500
=============
Weighted shares outstanding - diluted (3) 45,000
=============
(1)Effective tax rate of ~60% applied to GAAP earnings and
~40% applied to Non-GAAP adjustments
(2)Acquisition related items include expenses associated
with prior M&A activity and as incurred
(3)Weighted shares outstanding shown as pre "if-converted"
method
2012 Guidance Reconciliation of Non-GAAP Operating Margin %
FY 11 FY 12
Actual Guidance
---------- ----------
Gross Margin % [A] 79.3% ~76.0%
Non-GAAP Operating Expenses [B] 63.8% ~62.0%
Non-cash stock-based compensation 5.9% ~5.5%
Certain intellectual property litigation expenses 1.3% ~0.5%
Litigation award 18.7% -
Amortization of intangible assets 1.2% ~2.0%
Acquisition related items* 0.7% ~0.2%
Intangible asset impairment charge 3.4% -
---------- ----------
GAAP Operating Expenses 95.0% ~70.2%
---------- ----------
Non-GAAP Operating Margin % [A-B] 15.5% ~14.0%
---------- ----------
* Acquisition related items include expenses associated with prior M&A
activity and as incurred
Reconciliation of Non-GAAP Information Management uses certain Non-GAAP financial measures such as Non-GAAP earnings per share, which exclude non-cash stock-based compensation, certain intellectual property litigation expenses, a litigation award expense, amortization of intangible assets, acquisition related items, non-cash interest expense on convertible notes, a positive impact from certain transactions associated with convertible notes activity, certain discrete tax items, and an intangible asset impairment charge. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the Non-GAAP financial measures provided in this earnings release excluding these costs and uses these Non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these Non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These Non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from Non-GAAP measures used by other companies. Set forth below are reconciliations of the Non-GAAP financial measures to the comparable GAAP financial measure.
Reconciliation of Fourth Quarter 2011 Results
(Loss)
Pre-Tax Earnings
(in thousands, except per share data) Adjustments Net of Tax Per Share
----------- ----------- -----------
GAAP net loss $ (10,036) $ (0.24)
Impact of change from basic to
diluted share count -
----------- -----------
GAAP net loss, adjusted to diluted
share count $ (10,036) $ (0.24)
Non-cash stock-based compensation $ 8,281 5,134 0.12
Certain intellectual property
litigation expenses 1,254 777 0.02
Amortization of intangible assets 2,368 1,468 0.04
Acquisition related items 1,437 891 0.02
Non-cash interest expense on
convertible notes 3,033 1,880 0.04
Certain transactions associated
with convertible notes activity (390) (242) (0.01)
Certain discrete tax items 300 300 0.01
Intangible asset impairment charge 18,167 11,264 0.26
----------- -----------
Non-GAAP earnings $ 11,437 $ 0.27
=========== ===========
GAAP weighted shares outstanding -
basic and diluted 42,172
===========
Non-GAAP weighted shares outstanding
- diluted 42,690
===========
Reconciliation of Full Year 2011 Results
(Loss)
Pre-Tax Earnings
(in thousands, except per share data) Adjustments Net of Tax Per Share
----------- ----------- -----------
GAAP net loss $ (69,849) $ (1.73)
Impact of change from basic to
diluted share count 0.04
----------- -----------
GAAP net loss, adjusted to diluted
share count $ (69,849) $ (1.69)
Non-cash stock-based compensation $ 32,070 19,883 0.48
Certain intellectual property
litigation expenses 6,974 4,324 0.10
Litigation award 101,200 62,744 1.52
Amortization of intangible assets 6,609 4,098 0.10
Acquisition related items 3,774 2,340 0.06
Non-cash interest expense on
convertible notes 6,108 3,787 0.09
Certain transactions associated
with convertible notes activity (2,056) (1,275) (0.03)
Certain discrete tax items 6,616 6,616 0.16
Intangible asset impairment charge 18,167 11,264 0.27
----------- -----------
Non-GAAP earnings $ 43,932 $ 1.07
=========== ===========
GAAP weighted shares outstanding -
basic and diluted 40,372
===========
Non-GAAP weighted shares outstanding
- diluted 41,231
===========
Conference Call NuVasive will hold a conference call today at 5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com.
After the live webcast, the call will remain available on NuVasive's website, www.nuvasive.com, through March 23, 2012. In addition, a telephonic replay of the call will be available until March 7, 2012. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use pin number 385036.
About NuVasive NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 5th largest player in the $7.8 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With over 70 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive, Inc.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share data)
Three Months Ended
December 31, Year Ended December 31,
---------------------- ------------------------
2011 2010 2011 2010
---------- ---------- ----------- -----------
Revenue $ 150,194 $ 129,304 $ 540,506 $ 478,237
Cost of goods sold
(excluding amortization
of purchased technology) 37,062 23,102 112,111 85,139
---------- ---------- ----------- -----------
Gross profit 113,132 106,202 428,395 393,098
Operating expenses:
Sales, marketing and
administrative 92,732 82,018 346,757 312,122
Research and development 9,584 11,490 40,703 43,479
Amortization of
intangible assets 2,368 1,360 6,609 5,407
Intangible asset
impairment charge 18,167 - 18,167 -
Litigation award - - 101,200 -
---------- ---------- ----------- -----------
Total operating expenses 122,851 94,868 513,436 361,008
Interest and other
expense, net:
Interest income 241 193 832 760
Interest expense (6,971) (1,667) (17,933) (6,672)
Other (expense) income,
net (225) (345) 2,078 (264)
---------- ---------- ----------- -----------
Total interest and other
expense, net (6,955) (1,819) (15,023) (6,176)
---------- ---------- ----------- -----------
(Loss) income before
income taxes (16,674) 9,515 (100,064) 25,914
Income tax (benefit)
expense (6,328) (52,018) (29,043) (50,619)
---------- ---------- ----------- -----------
Consolidated net (loss)
income $ (10,346) $ 61,533 $ (71,021) $ 76,533
========== ========== =========== ===========
Net loss attributable to
noncontrolling interests $ (310) $ (399) $ (1,172) $ (1,752)
========== ========== =========== ===========
Net (loss) income
attributable to NuVasive,
Inc. $ (10,036) $ 61,932 $ (69,849) $ 78,285
========== ========== =========== ===========
Net (loss) income per
share attributable to
NuVasive, Inc.:
Basic $ (0.24) $ 1.57 $ (1.73) $ 1.99
========== ========== =========== ===========
Diluted $ (0.24) $ 1.39 $ (1.73) $ 1.85
========== ========== =========== ===========
Weighted average shares
outstanding:
Basic 42,172 39,486 40,372 39,251
========== ========== =========== ===========
Diluted 42,172 45,488 40,372 45,514
========== ========== =========== ===========
Stock-based compensation is included
in operating expenses in the
following categories:
Sales, marketing and
administrative $ 7,627 $ 6,099 $ 29,583 $ 24,945
Research and development 654 822 2,487 3,280
---------- ---------- ----------- -----------
$ 8,281 $ 6,921 $ 32,070 $ 28,225
========== ========== =========== ===========
NuVasive, Inc.
Unaudited Condensed Consolidated Balance Sheets
(in thousands)
December 31,
------------------------
2011 2010
----------- -----------
ASSETS
Current assets:
Cash and cash equivalents $ 163,492 $ 92,597
Short-term marketable securities 146,228 86,458
Accounts receivable, net 88,350 74,361
Inventory 119,313 107,577
Deferred tax assets 54,550 4,425
Prepaid expenses and other current assets 19,904 6,353
----------- -----------
Total current assets 591,837 371,771
Property and equipment, net 124,754 102,165
Long-term marketable securities 32,503 50,635
Intangible assets, net 108,140 107,121
Goodwill 159,349 103,070
Deferred tax assets, non-current 19,857 52,033
Restricted cash and investments 68,600 5,529
Other assets 18,522 9,705
----------- -----------
Total assets $ 1,123,562 $ 802,029
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 51,744 $ 58,995
Accrued payroll and related expenses 22,215 17,266
Litigation liability 101,200 -
Acquisition-related liabilities 32,221 32,715
----------- -----------
Total current liabilities 207,380 108,976
Senior Convertible Notes 394,019 230,000
Long-term acquisition-related liabilities - 326
Deferred tax liabilities 3,952 3,685
Other long-term liabilities 13,461 12,810
Commitments and contingencies
Noncontrolling interests 10,705 11,877
Stockholders' equity:
Common stock 42 40
Additional paid-in capital 674,790 545,114
Accumulated other comprehensive income 477 616
Accumulated deficit (181,264) (111,415)
----------- -----------
Total stockholders' equity 494,045 434,355
----------- -----------
Total liabilities and stockholders' equity $ 1,123,562 $ 802,029
----------- -----------
NuVasive, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands)
Year Ended December 31,
----------------------------------
2011 2010 2009
---------- ---------- ----------
Operating activities:
Consolidated net (loss) income $ (71,021) $ 76,533 $ 4,437
Adjustments to reconcile net (loss)
income to net cash provided by
operating activities:
Depreciation and amortization 36,242 36,737 29,841
Deferred income tax benefit (30,967) (53,664) -
Amortization of debt discount 6,108 - -
Amortization of debt issuance costs 1,816 1,493 1,493
Stock-based compensation 32,070 28,225 23,793
Intangible asset impairment charge 18,167 - -
Loss on repurchase of Senior
Convertible Notes, net 332 - -
Gain recognized on change in fair
value of derivatives (2,387) - -
Leasehold abandonment (reversal) - - (1,997)
Allowance for doubtful accounts and
sales return reserve 1,345 (995) 2,211
Allowance for excess and obsolete
inventory, net of write-offs 6,028 1,607 2,297
Accretion of contingent
consideration 980 962 5
Other non-cash adjustments 5,247 3,844 1,861
Changes in operating assets and
liabilities, net of effects from
acquisitions:
Accounts receivable (9,929) (17,865) (7,828)
Inventory (17,170) (18,664) (23,133)
Prepaid expenses and other current
assets (14,396) (2,105) 6
Accounts payable and accrued
liabilities (3,385) 11,596 5,932
Litigation liability 101,200 -
Accrued payroll and related expenses 2,685 (1,877) 7,501
---------- ---------- ----------
Net cash provided by operating
activities 62,965 65,827 46,419
Investing activities:
Cash paid for acquisitions and
investments (35,375) (973) (46,055)
Purchases of property and equipment (53,370) (45,846) (32,878)
Purchases of marketable securities (253,210) (203,415) (157,278)
Sales of marketable securities 151,966 204,439 108,308
Purchases of restricted investment (4,536) - -
Payment for specific rights in
connection with supply agreement,
net of refund received (5,000) - -
Other assets (2,199) - -
---------- ---------- ----------
Net cash used in investing activities (201,724) (45,795) (127,903)
Financing activities:
Proceeds from the sale of warrants 47,898 - -
Proceeds from the issuance of
convertible debt, net of issuance
costs 391,445 - -
Purchase of convertible note hedges (80,097) - -
Repurchase of 2013 Senior
Convertible Notes (154,164) - -
Tax benefits related to stock-based
compensation awards 463 186 1,902
Proceeds from the issuance of common
stock 6,852 14,831 12,556
Payment of contingent consideration (1,800) - -
Other assets (718) (7,935) -
---------- ---------- ----------
Net cash provided by financing
activities 209,879 7,082 14,458
Effect of exchange rate changes on
cash (225) 70 121
---------- ---------- ----------
Increase (decrease) in cash and cash
equivalents 70,895 27,184 (66,905)
Cash and cash equivalents at beginning
of year 92,597 65,413 132,318
---------- ---------- ----------
Cash and cash equivalents at end of year $ 163,492 $ 92,597 $ 65,413
========== ========== ==========
Contact:
Michael J. Lambert
EVP & Chief Financial Officer
NuVasive, Inc.
858-909-3394
Email Contact
Investors:
Patrick F. Williams
Vice President, Industry & Investor Relations
NuVasive, Inc.
858-638-5511
Email Contact
Media:
Nicholas S. Laudico
The Ruth Group
646-536-7030
Email Contact
SOURCE: NuVasive, Inc.